CBD Life Sciences Inc.
Other OTCTotal Valuation
CBD Life Sciences Inc. carries a market capitalization of 488,012.00, placing it among publicly traded companies globally.
| Market Cap | 488,012.00 |
| Enterprise Value | N/A |
Share Statistics
CBD Life Sciences Inc. currently has 11.00 shares outstanding.
| Shares Outstanding | 11.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
CBD Life Sciences Inc. maintains a current ratio of 5.22, meaning it holds 5.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.22 |
| Quick Ratio | 5.22 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -25.42 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -15.87 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
CBD Life Sciences Inc.'s stock has gained approximately 30% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 30% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, CBD Life Sciences Inc. generated 122,789.00 in revenue and converted that into -103,109.00 in net income, yielding earnings per share of -9,373.55. EBITDA reached -90,900.00, while operating income came in at -95,675.00.
| Revenue | 122,789.00 |
| Gross Profit | 122,789.00 |
| Operating Income | -95,675.00 |
| Pretax Income | -103,109.00 |
| Net Income | -103,109.00 |
| EBITDA | -90,900.00 |
| EBIT | -95,675.00 |
| Earnings Per Share (EPS) | -9,373.55 |
Balance Sheet
Total book value stands at -972,555.00, with working capital of 279,969.00 providing operational flexibility.
| Cash & Cash Equivalents | N/A |
| Total Debt | N/A |
| Net Debt | N/A |
| Equity (Book Value) | -972,555.00 |
| Book Value Per Share | -88,414.09 |
| Working Capital | 279,969.00 |
Cash Flow
CBD Life Sciences Inc. produced -125,354.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -125,354.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -125,354.00 |
| FCF Per Share | -11,395.82 |
Margins
CBD Life Sciences Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -77.92 and net profit margin of -83.97 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -77.92 |
| Pretax Margin | -83.97 |
| Profit Margin | -83.97 |
| EBITDA Margin | -74.03 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -126,620.20 |
| FCF Yield | -126,620.20 |
Stock Splits
CBD Life Sciences Inc.'s most recent stock split took place on April 22, 2024 with a 300:1 split ratio.
| Last Split Date | 4/22/2024 |
| Split Ratio | 300:1 |
Scores
CBD Life Sciences Inc. posts an Altman Z-Score of -12.24, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -12.24 |